PSYCHOGENICS, INC.

Address

765 OLD SAW MILL RIVER RD
TARRYTOWN, NY, 10591-6702

Information

DUNS: 4812744
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Predictive Smoking Cessation Preclinical Battery

    Amount: $829,176.00

    DESCRIPTION (provided by applicant): Despite great advances in both the understanding of the neurobiology of addiction and the development and approval of smoking cessation therapies, a significant ne ...

    SBIRPhase I2012Department of Health and Human Services
  2. Eltoprazine for the Treatment of Cognitive Dysfunction Assoc. With Schizophrenia

    Amount: $700,000.00

    DESCRIPTION (provided by applicant): Schizophrenia is a common and highly disabling psychiatric disorder with a population prevalence around 1%. The manifestations of schizophrenia fall into three maj ...

    SBIRPhase I2011Department of Health and Human Services
  3. Prodrugs of NAAG Peptidase Inhibitors for the Treatment of Schizophrenia

    Amount: $620,426.00

    DESCRIPTION (provided by applicant): Schizophrenia is a chronic, severe, and disabling brain disease. Nearly 1 percent of the population develops schizophrenia during their lifetime - more than 2 mill ...

    SBIRPhase I2008Department of Health and Human Services
  4. HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment

    Amount: $366,682.00

    DESCRIPTION (provided by applicant): Pancreatic cancer is the fifth leading cause of cancer death in the US. Despite tremendous efforts aimed at understanding its molecular biology, conventional treat ...

    SBIRPhase I2008Department of Health and Human Services
  5. NAAG Peptidase Inhibitors for the Treatment of Traumatic Brain Injury

    Amount: $760,811.00

    DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is a serious public health concern. It is estimated that severe TBI will become the third most common cause of death and disability gl ...

    SBIRPhase I2008Department of Health and Human Services
  6. High Throughput in Vivo Drug Discovery- Phase II

    Amount: $1,350,000.00

    DESCRIPTION (provided by applicant): This Phase II application is being submitted in response to a continuing NIMH program announcement for Pharmacological Agents and Drugs for Mental Disorders. The g ...

    SBIRPhase II2008Department of Health and Human Services
  7. Nicotinic Ligands as Smoking Cessation Agents

    Amount: $288,900.00

    DESCRIPTION (provided by applicant): Tobacco use and nicotine addiction are an immense burden on the public health. There are an estimated 44.5 million (21%) adult smokers and an estimated 3.75 millio ...

    STTRPhase I2007Department of Health and Human Services
  8. Development of GSK-3 Beta Inhibitors for the Treatment of Parkinson's Disease

    Amount: $282,568.00

    DESCRIPTION (provided by applicant): Parkinson's disease (PD), a chronic and progressive neurological condition and one of aging and age- related diseases, affects approximately 1.5 million people in ...

    SBIRPhase I2007Department of Health and Human Services
  9. High Throughput Behavioral Testing For Novel Antidepressants

    Amount: $250,000.00

    DESCRIPTION (provided by applicant): CONFIDENTIAL Project Summary/Abstract This application is being submitted in response to an NIMH program announcement for Pharmacological Agents and Drugs for Ment ...

    SBIRPhase I2007Department of Health and Human Services
  10. Piperidine-Based Compounds as Therapeutics for Narcolepsy-Cataplexy

    Amount: $250,000.00

    DESCRIPTION (provided by applicant): Sleep deprivation and sleep disorders are estimated to cost Americans over $100 billion annually in lost productivity, medical expenses, sick leave, and property a ...

    SBIRPhase I2007Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government